NCT02238106View on ClinicalTrials.gov

Salmeterol Inhalation Powder Administered as the Xinafoate Salt From Hard Polyethylene Capsules Via the HandiHaler® 2, and Serevent® Diskus® in Patients With Chronic Obstructive Pulmonary Disease (COPD)

PHASE2CompletedINTERVENTIONAL
Enrollment

136

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

February 28, 2006

Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
DRUG

Salmeterol medium dose

DRUG

Salmeterol low dose

DRUG

Salmeterol high dose

DRUG

Serevent® Diskus®

DRUG

Placebo HandiHaler®

DRUG

Placebo Diskus®

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT02238106 - Salmeterol Inhalation Powder Administered as the Xinafoate Salt From Hard Polyethylene Capsules Via the HandiHaler® 2, and Serevent® Diskus® in Patients With Chronic Obstructive Pulmonary Disease (COPD) | Biotech Hunter | Biotech Hunter